CTI BioPharma Corp. [CTIC] Stock trading around $5.94 per share: What’s Next?

Related

CTI BioPharma Corp. [NASDAQ: CTIC] stock went on an upward path that rose over 9.39% on Wednesday, amounting to a one-week price increase of more than 14.89%. The company report on May 27, 2022 that CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved on May 27, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received options to purchase an aggregate of 94,000 shares of CTI BioPharma common stock. The options will be issued upon each employee’s grant date (the “Grant Date”), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee’s Grant Date, subject to the employee’s continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

Over the last 12 months, CTIC stock rose by 149.58%. The one-year CTI BioPharma Corp. stock forecast points to a potential upside of 37.67. The average equity rating for CTIC stock is currently 1.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $629.40 million, with 99.83 million shares outstanding and 74.15 million shares in the current float. Compared to the average trading volume of 6.33M shares, CTIC stock reached a trading volume of 4522147 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on CTI BioPharma Corp. [CTIC]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTIC shares is $9.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTIC stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BTIG Research have made an estimate for CTI BioPharma Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 09, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on May 06, 2021, representing the official price target for CTI BioPharma Corp. stock. Previously, the target price had yet another raise to $3, while JMP Securities analysts kept a Mkt Outperform rating on CTIC stock.

The Average True Range (ATR) for CTI BioPharma Corp. is set at 0.46, with the Price to Sales ratio for CTIC stock in the period of the last 12 months amounting to 273.65.

CTIC Stock Performance Analysis:

CTI BioPharma Corp. [CTIC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.89. With this latest performance, CTIC shares gained by 11.24% in over the last four-week period, additionally plugging by 164.00% over the last 6 months – not to mention a rise of 149.58% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTIC stock in for the last two-week period is set at 67.14, with the RSI for the last a single of trading hit 74.72, and the three-weeks RSI is set at 63.37 for CTI BioPharma Corp. [CTIC]. The present Moving Average for the last 50 days of trading for this stock 4.81, while it was recorded at 5.48 for the last single week of trading, and 3.19 for the last 200 days.

Insight into CTI BioPharma Corp. Fundamentals:

CTI BioPharma Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.

CTI BioPharma Corp. [CTIC] Insider Position Details

There are presently around $324 million, or 56.90% of CTIC stock, in the hands of institutional investors. The top three institutional holders of CTIC stocks are: BVF INC/IL with ownership of 8,929,690, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 7,140,450 shares of the stock with an approximate value of $38.77 million in CTIC stocks shares; and LION POINT CAPITAL, LP, currently with $29.81 million in CTIC stock with ownership of nearly 348.641% of the company’s market capitalization.

55 institutional holders increased their position in CTI BioPharma Corp. [NASDAQ:CTIC] by around 21,997,711 shares. Additionally, 22 investors decreased positions by around 10,109,975 shares, while 17 investors held positions by with 27,521,010 shares. The mentioned changes placed institutional holdings at 59,628,696 shares, according to the latest SEC report filing. CTIC stock had 31 new institutional investments in for a total of 6,875,635 shares, while 4 institutional investors sold positions of 2,239,345 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]